Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG2b|
|Immunogen||Recombinant human MGMT (O6-methylguanine-DNA methyltransferase) purified from E. coli|
|Contains||0.02% sodium azide|
|Storage Conditions||Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.|
|Tested Applications||Dilution *|
|Flow Cytometry (Flow)||1:10-1:1000|
|Immunohistochemistry (Paraffin) (IHC (P))||1:500-1:1000|
|Western Blot (WB)||1:1000|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
Suggested positive control: CEM-CCRF cells.
TK6 cells as a negative control.
O6-Methylguanine-DNA Methyltransferase (MGMT) is an important DNA repair protein involved in tumor cell resistance to the cytotoxic activity of chemotherapeutic alkylating agents. This protein is also effective in protecting normal cells against the genotoxic and carcinogenic effects of DNA alkylation. The alkylating drug resistance is caused by MGMT's ability to remove DNA alkyl groups introduced in the O6 position of guanine. MGMT is expressed in highly variable amounts, depending upon the cell and tissue type, species, and cellular growth characteristics. In addition, MGMT activity varies among groups of tumors and within a particular type of tumor.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide.
MA3-16537 was used in immunohistochemistry - paraffin section to discuss the use of temozolomide to treat pituitary tumors
|Bengtsson D,Schrøder HD,Andersen M,Maiter D,Berinder K,Feldt Rasmussen U,Rasmussen ÅK,Johannsson G,Hoybye C,van der Lely AJ,Petersson M,Ragnarsson O,Burman P||The Journal of clinical endocrinology and metabolism (100:1689)||2015|
MGMT expression and pituitary tumours: relationship to tumour biology.
MA3-16537 was used in immunohistochemistry to perform a comparative study the gene expression profiles and cancer biology of pituitary tumors classified as high or low expressors of MGMT
|McCormack A,Kaplan W,Gill AJ,Little N,Cook R,Robinson B,Clifton-Bligh R||Pituitary (16:208)||2013|
O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation is a rare event in soft tissue sarcoma.
MA3-16537 was used in immunohistochemistry to study the frequency of MGMT promoter methylation in soft tissue sarcomas
|Jakob J,Hille M,Sauer C,Ströbel P,Wenz F,Hohenberger P||Radiation oncology (London, England) (7:null)||2013|
Salvage therapy with temozolomide in patients with aggressive or metastatic pituitary adenomas: experience in six cases.
MA3-16537 was used in immunohistochemistry to discuss the therapeutic benefic of temozolomide treatment in patients with aggressive or metastatic pituitary adenomas
|Losa M,Mazza E,Terreni MR,McCormack A,Gill AJ,Motta M,Cangi MG,Talarico A,Mortini P,Reni M||European journal of endocrinology / European Federation of Endocrine Societies (163:843)||2010|
Low O6-methylguanine-DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours.
MA3-16537 was used in immunohistochemistry to investigate the association between O6-methylguanine-DNA methyltransferase expression and temozolomide therapy in aggressive pituitary tumours
|McCormack AI,McDonald KL,Gill AJ,Clark SJ,Burt MG,Campbell KA,Braund WJ,Little NS,Cook RJ,Grossman AB,Robinson BG,Clifton-Bligh RJ||Clinical endocrinology (71:226)||2009|
6-O-methylguanine-DNA methyltransferase; methylated DNA protein cysteine methyltransferase; METHYLGUANINE-DNA METHYLTRANSFERASE; MGMT: O-6-methylguanine-DNA methyltransferase; O-6-methylguan; O-6-methylguanine-DNA-alkyltransferase; O6-methylguanine-DNA methyltransferase